StockData
Aytu BioPharma, Inc logo

Aytu BioPharma, Inc (AYTU) stock

AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3070% below fair value
$2.66+0.84 (+46.15%)

Close on Nov 17, 2026Market cap $28.91MP/E –Yield –

Aytu BioPharma r&d expenses

Research and development expenses are spending on new products and technology.

Aytu BioPharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $0, down 100.0% year over year. For fiscal 2026 it was $0, down 100.0% from the year before. The highest annual figure on record is $12.66M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Jun 30, 2026$0-100.0%
FY2025Jun 30, 2025$1.33M-52.1%
FY2024Jun 30, 2024$2.77M-32.4%
FY2023Jun 30, 2023$4.10M-67.7%
FY2022Jun 30, 2022$12.66M+125.2%
FY2021Jun 30, 2021$5.62M+226.5%
FY2020Jun 30, 2020$1.72M+192.3%
FY2019Jun 30, 2019$589.07K+251.5%
FY2018Jun 30, 2018$167.60K-82.5%
FY2017Jun 30, 2017$959.86K-84.3%
FY2016Jun 30, 2016$6.13M+90.3%
FY2015Jun 30, 2015$3.22M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jun 30, 2026$0-100.0%
Q3 FY2026CQ1 2026Mar 31, 2026$0-100.0%
Q2 FY2026CQ4 2025Dec 31, 2025$0-100.0%
Q1 FY2026CQ3 2025Sep 30, 2025$0-100.0%
Q4 FY2025CQ2 2025Jun 30, 2025$216.00K-79.3%
Q3 FY2025CQ1 2025Mar 31, 2025$162.00K-73.5%
Q2 FY2025CQ4 2024Dec 31, 2024$522.00K+0.2%
Q1 FY2025CQ3 2024Sep 30, 2024$426.00K-28.4%
Q4 FY2024CQ2 2024Jun 30, 2024$1.04M+124.1%
Q3 FY2024CQ1 2024Mar 31, 2024$611.00K-28.6%
Q2 FY2024CQ4 2023Dec 31, 2023$521.00K-69.5%
Q1 FY2024CQ3 2023Sep 30, 2023$595.00K-44.1%
Q4 FY2023CQ2 2023Jun 30, 2023$465.00K-85.7%
Q3 FY2023CQ1 2023Mar 31, 2023$856.00K-73.9%
Q2 FY2023CQ4 2022Dec 31, 2022$1.71M-61.8%
Q1 FY2023CQ3 2022Sep 30, 2022$1.06M-35.6%
Q4 FY2022CQ2 2022Jun 30, 2022$3.25M-31.7%
Q3 FY2022CQ1 2022Mar 31, 2022$3.28M+741.5%
Q2 FY2022CQ4 2021Dec 31, 2021$4.48M+1464.7%
Q1 FY2022CQ3 2021Sep 30, 2021$1.65M+802.7%
Q4 FY2021CQ2 2021Jun 30, 2021$4.76M+217.9%
Q3 FY2021CQ1 2021Mar 31, 2021$390.00K+396.8%
Q2 FY2021CQ4 2020Dec 31, 2020$286.00K+328.9%
Q1 FY2021CQ3 2020Sep 30, 2020$183.00K+134.6%
Q4 FY2020CQ2 2020Jun 30, 2020$1.50M+755.2%
Q3 FY2020CQ1 2020Mar 31, 2020$78.50K-27.9%
Q2 FY2020CQ4 2019Dec 31, 2019$66.68K-55.3%
Q1 FY2020CQ3 2019Sep 30, 2019$78.02K-49.9%
Q4 FY2019CQ2 2019Jun 30, 2019$175.26K-7.7%
Q3 FY2019CQ1 2019Mar 31, 2019$108.90K-4.6%
Q2 FY2019CQ4 2018Dec 31, 2018$149.03K–
Q1 FY2019CQ3 2018Sep 30, 2018$155.88K+10.6%
Q4 FY2018CQ2 2018Jun 30, 2018$189.99K+2.5%
Q3 FY2018CQ1 2018Mar 31, 2018$114.14K-59.1%
Q2 FY2018CQ4 2017Dec 31, 2017-$277.49K-205.3%
Q1 FY2018CQ3 2017Sep 30, 2017$140.95K-39.2%
Q4 FY2017CQ2 2017Jun 30, 2017$185.33K–
Q3 FY2017CQ1 2017Mar 31, 2017$279.05K–
Q2 FY2017CQ4 2016Dec 31, 2016$263.46K–
Q1 FY2017CQ3 2016Sep 30, 2016$232.02K–

More Aytu BioPharma figures

See a number that looks wrong?